@onclive.bsky.social🗓️ September GI cancer news brought data, approvals, and plenty of expert perspectives. @cityofhope.bsky.social #OncologyUnplugged #crcsm #oncology
Sign up to read a recap of the news & insights we reported ➡️: www.onclive.com/view/gi-canc...
@onclive.bsky.social
@academaxjournals.bsky.socialGreat find, @sgregurick.bsky.social!
Single-cell and spatial transcriptomics are giving us a clearer view of the unfolded protein response in tumors.
@academaxjournals.bsky.social celebrates research that moves science forward.
Explore similar STEM research with us!
@drtimos.bsky.social🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVsc9b !
@purescience.newsBowel cancer “melted away” after immunotherapy, then stayed away #Science #HealthandMedicine #Oncology #immunotherapy #bowelcancer #neoprismcrc #cancerresearch #pembrolizumab
@purescience.newsYour Gut Bacteria May Reveal How Cancer Treatment Will Affect You #Science #HealthandMedicine #Oncology #guthealth #cancerresearch #mayoclinic #chemotherapy #microbiome
@newsramp.comLantern Pharma (NASDAQ: LTRN) secures Taiwan approvals to advance Part 2 of its Phase 2 HARMONIC trial for LP-300, targeting EGFR L858R mutation patients. U.S. sites also begin identifying eligible patients as the trial expands. #Oncology #ClinicalTrials
@sigtrans-sttt.bsky.socialHow do intrinsic and acquired mechanisms drive cancer drug resistance?
This review details the mechanisms underlying resistance, highlighting emerging therapeutic strategies for overcoming resistance in #PrecisionOncology.
#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerResearch #Oncology
@asidejournals.comCall for submissions — ASIDE Oncology
Original research, reviews and case reports. No fee to submit or publish. Double-anonymous peer review, CC BY 4.0, Crossref DOIs.
#Oncology #OpenAccess #CallForPapers
https://asidejournals.com/index.php/oncology/Call-for-Submissions
@drtimos.bsky.social🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TVs6b9
@ASCO
#SocialListening #LucidQuest
@meducationai.bsky.socialA new FDA approval in heme/onc. Does it matter for your patients? Set up OncoPulse once and the approvals in the cancers you treat come to your inbox. Free.
@gmj-georgia.bsky.socialA new AI framework teaches neural networks to recognise when they encounter unfamiliar cancer subtypes—preventing overconfident mi… #Artificialintelligence #Cancerdiagnosis #MedicalAI #Oncology #Uncertaintyquantification #Artificialintelligence #Cancerdiagnosis #MedicalAI #Oncology #Uncertainty…
@onclive.bsky.social📰 The Guardant360 CDx has received EU approval as a companion diagnostic to identify patients with ER+, HER2– locally advanced or metastatic breast cancer who may benefit from camizestrant. #bcsm #oncology
Full story ➡️: www.onclive.com/view/guardan...
@onclive.bsky.socialHow are experts navigating subcutaneous therapy administrations in multiple myeloma? Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, break down newer patient-centric approaches #mmsm #oncology
Listen now: www.onclive.com/view/navigat...
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) appoints Raju Willener as CFO, bringing 30+ years of global capital markets expertise as the company advances its BiTAC oncology platform, including antibody-drug conjugates and T-cell engagers. #Biotech #Oncology
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comOnco-Innovations (ONCO) is advancing ONC010 toward first-in-human trials, completing a high-purity drug batch, progressing preclinical studies and aligning regulatory planning for a potential Phase I study. #Oncology #Biotech
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) debuts on U.S. markets with its precision 'AND-gated' BiTAC cancer platform, early preclinical proof of concept, $27.5M in financing, and two key executive hires. A Swiss biotech to watch. #Oncology #Biotech
@newsramp.comLantern Pharma (NASDAQ: LTRN) receives USPTO Notice of Allowance for LP-284 blood cancer treatment patent, extending IP protection through 2042. The AI-developed therapy targets mantle cell lymphoma and double-hit lymphoma. #Oncology #Biotech
